Obalon® Secures $16.5 Million Series C Financing and Achieves Key Milestones in Providing a Novel, Nonsurgical Device for Weight Loss
15:59 EDT 18 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Obalon Therapeutics, Inc. announced it closed a $16.5 million Series C
private equity financing, began enrolling patients in a U.S. clinical
trial, received CE Mark approval and had weight loss data presented at
the IFSO Europea...
Other Sources for this Article
Obalon Therapeutics, Inc.
Andy Rasdal, CEO
+1.760.795.6557
arasdal@obalon.com
www.obalon.com
More From BioPortfolio on "Obalon® Secures $16.5 Million Series C Financing and Achieves Key Milestones in Providing a Novel, Nonsurgical Device for Weight Loss"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
